How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Document

    • Has all of the relevant evidence been taken into account?

  • Question on Document

    Are the summaries of clinical and resource savings reasonable interpretations of the evidence?

  • Question on Document

    • Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Document

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, gender, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity? (optional, max 300 words)

Draft guidance consultation

Open for comments Open until   Request commenting lead permission

We have updated this service so that members of the same organisation can now collaborate on a joint online response.

Read our blog to learn more.

2 Information about pembrolizumab

Marketing authorisation indication

2.1

Pembrolizumab (Keytruda, MSD) 'in combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy), is indicated for the treatment of FIGO 2014 Stage 3 – 4A locally advanced cervical cancer in adults who have not received prior definitive therapy'.

Dosage in the marketing authorisation

Price

2.3

Pembrolizumab costs £2,630 per 100‑mg vial (excluding VAT; BNF online accessed January 2026), or around £91,000 for a year of treatment. The company has a commercial arrangement, which would have applied if pembrolizumab had been recommended.

Sustainability

2.4

Information on the Carbon Reduction Plan for UK carbon emissions for MSD will be included here when guidance is published.